Polaris Group (6550.TW)

TWD 38.0

(-5.59%)

EBITDA Summary of Polaris Group

  • Polaris Group's latest annual EBITDA in 2023 was -1.38 Billion TWD , down -68.83% from previous year.
  • Polaris Group's latest quarterly EBITDA in 2024 Q2 was -492.56 Million TWD , down -42.55% from previous quarter.
  • Polaris Group reported an annual EBITDA of -981.37 Million TWD in 2022, down -75.45% from previous year.
  • Polaris Group reported an annual EBITDA of -570.96 Million TWD in 2021, down -6.08% from previous year.
  • Polaris Group reported a quarterly EBITDA of -492.56 Million TWD for 2024 Q2, down -42.55% from previous quarter.
  • Polaris Group reported a quarterly EBITDA of -566.76 Million TWD for 2023 Q4, down -23.24% from previous quarter.

Annual EBITDA Chart of Polaris Group (2023 - 2016)

Created with Highcharts 11.1.0YearsEBITDA20162017201820192020202120222023-1500000000 TWD-1250000000 TWD-1000000000 TWD-750000000 TWD-500000000 TWD-250000000 TWD

Historical Annual EBITDA of Polaris Group (2023 - 2016)

Year EBITDA EBITDA Growth
2023 -1.38 Billion TWD -68.83%
2022 -981.37 Million TWD -75.45%
2021 -570.96 Million TWD -6.08%
2020 -516.08 Million TWD 17.07%
2019 -655.1 Million TWD 27.27%
2018 -886.7 Million TWD -23.74%
2017 -738.56 Million TWD 10.98%
2016 -801.89 Million TWD 0.0%

Peer EBITDA Comparison of Polaris Group

Name EBITDA EBITDA Difference
Apex Biotechnology Corp. 221.06 Million TWD 728.561%
Sinphar Pharmaceutical Co.,Ltd. 582.94 Million TWD 338.359%
Panion & Bf Biotech Inc. 327.21 Million TWD 524.639%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. 473.81 Million TWD 393.258%
GenMont Biotech Incorporation 71.76 Million TWD 2036.097%
Abnova (Taiwan) Corporation 81.2 Million TWD 1811.015%
Adimmune Corporation -512.42 Million TWD -171.16%
Tanvex BioPharma, Inc. -1.75 Billion TWD 20.802%
Energenesis Biomedical CO.,LTD. -244.57 Million TWD -468.123%
UnicoCell Biomed Co., Ltd. -56.27 Million TWD -2369.077%
PELL Bio-Med Technology Co. Ltd. -353.17 Million TWD -293.427%